Analysts Set Metagenomi, Inc. (NASDAQ:MGX) PT at $10.00

Metagenomi, Inc. (NASDAQ:MGX) has earned an average rating of “Moderate Buy” from the five analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $10.00.

MGX has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Metagenomi from a “sell” rating to a “hold” rating in a report on Saturday, October 25th. Zacks Research upgraded Metagenomi from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Metagenomi in a report on Monday, December 22nd.

Hedge Funds Weigh In On Metagenomi

A number of institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its holdings in shares of Metagenomi by 4,155.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 62,559 shares of the company’s stock worth $148,000 after buying an additional 61,089 shares during the period. Bank of America Corp DE lifted its position in Metagenomi by 508.5% during the 3rd quarter. Bank of America Corp DE now owns 18,766 shares of the company’s stock worth $44,000 after acquiring an additional 15,682 shares during the last quarter. Man Group plc acquired a new position in Metagenomi during the 3rd quarter worth $125,000. Two Sigma Investments LP boosted its holdings in Metagenomi by 1,394.4% during the third quarter. Two Sigma Investments LP now owns 207,528 shares of the company’s stock valued at $492,000 after acquiring an additional 193,641 shares during the period. Finally, Bridgeway Capital Management LLC grew its position in shares of Metagenomi by 98.4% in the third quarter. Bridgeway Capital Management LLC now owns 195,800 shares of the company’s stock valued at $464,000 after purchasing an additional 97,100 shares during the last quarter.

Metagenomi Stock Performance

Shares of MGX opened at $1.45 on Thursday. The firm has a market cap of $54.45 million, a PE ratio of -0.60 and a beta of 0.50. The firm’s 50 day moving average price is $1.69 and its 200 day moving average price is $2.02. Metagenomi has a twelve month low of $1.23 and a twelve month high of $3.95.

Metagenomi (NASDAQ:MGX) last posted its earnings results on Wednesday, November 12th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.05. The company had revenue of $8.66 million during the quarter, compared to the consensus estimate of $7.82 million. Metagenomi had a negative net margin of 287.06% and a negative return on equity of 43.19%. On average, sell-side analysts anticipate that Metagenomi will post -2.46 earnings per share for the current fiscal year.

About Metagenomi

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.